Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectiveness Study in a Population-Based Sample

PURPOSE: Epidermal growth factor receptor (EGFR) inhibitors are approved for treating metastatic colorectal cancer (CRC); KRAS mutation testing is recommended prior to treatment. We conducted a non-inferiority analysis to examine whether KRAS testing has impacted survival in CRC patients. PATIENTS A...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Feigelson, Heather Spencer, Zeng, Chan, Pawloski, Pamala A., Onitilo, Adedayo A., Richards, C. Sue, Johnson, Monique A., Kauffman, Tia L., Webster, Jennifer, Nyirenda, Carsie, Alexander, Gwen L., Hwang, Clara, Cross, Deanna, McCarty, Catherine A., Davis, Robert L., Schwarzkopf, Denise, Williams, Andrew E., Honda, Stacey, Daida, Yihe, Kushi, Lawrence H., Delate, Thomas, Goddard, Katrina A. B.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2014
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4006772/
https://ncbi.nlm.nih.gov/pubmed/24788807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0094977
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller